Test Price
2,800 AED✅ Home Collection Available
CDKN2A Gene Familial Melanoma and Neural System Tumor Syndrome Genetic Test (NGS) in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑15189 Accredited Next‑Generation Sequencing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily from 8 AM to 11 PM).
Clinical Guidance: Telephonic Post‑Test Clinical Guidance for result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The CDKN2A gene NGS test identifies germline mutations associated with familial atypical multiple mole melanoma (FAMMM) syndrome and neural system tumors. This comprehensive analysis enables personalized risk assessment, targeted surveillance, and informed preventive strategies for individuals with a strong family history.
| Feature | Our CDKN2A NGS Test | Single‑Gene PCR |
|---|---|---|
| Methodology | Next‑Generation Sequencing (NGS) – full gene coverage | PCR‑based hotspot assay |
| Sensitivity | 99.9% (complete CDKN2A coding regions & splice sites) | ~80% (limited to known mutations) |
| Turnaround Time | 3–4 Weeks | 6+ Weeks |
Physician Insight & Safety Protocols
"Understanding your genetic predisposition to melanoma and neural system tumours empowers proactive health management. A positive CDKN2A mutation result does not guarantee cancer development; it enables personalised surveillance and prevention strategies tailored to your family history. Please discuss all findings with your genetic counsellor and oncologist."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA License: 9294403)
Advisory: Medication Safety
⚠ Do not discontinue prescribed medication without consulting your doctor.
Exclusion Criteria & Red Flags
- This test is indicated for individuals with a strong family history of melanoma, multiple atypical nevi, or neural system tumors. It is not a routine screening for asymptomatic, low‑risk individuals.
- If prior to receiving results you experience new neurological symptoms (seizures, severe headaches, vision changes) or changes in moles following the ABCDE criteria (Asymmetry, Border irregularity, Color variation, Diameter >6mm, Evolution), seek immediate medical attention.
- Ensure informed consent and genetic counselling have been completed as per Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Patient FAQ & Clinical Guidance
1. What is the CDKN2A genetic test for?
The CDKN2A gene test detects inherited mutations linked to familial melanoma and neural system tumor syndromes. Results guide lifelong screening frequency, dermatological surveillance, and preventive interventions.
2. How is the sample collected and what is the turnaround time?
A whole blood, saliva, or FTA card (dried blood spot) sample is collected via our temperature‑controlled VIP Mobile Phlebotomy service. Results are typically available within 3–4 weeks from sample receipt.
3. Is genetic counselling required?
Yes, pre‑test genetic counselling is mandatory. You will meet with a consultant medical geneticist to draw a pedigree chart, discuss the implications of a CDKN2A mutation, and provide informed consent.
UAE Regulatory & Data Privacy Adherence
Data Protection: All genetic data is processed in strict compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your information is encrypted, anonymized for analysis, and never shared without consent.
Licensing: DNA Labs UAE operates under DHA Facility License Number 1143, ensuring every test meets the highest clinical and ethical standards.
Clinical & Logistical Metadata
| Test Name | CDKN2A Gene Familial Melanoma and Neural System Tumor Syndrome Genetic Test (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (Peripheral), Saliva, or FTA Card (Dried Blood Spot) |
| Methodology Used | Next‑Generation Sequencing (NGS) – Full Gene Sequencing |
| ICD‑10‑CM Code | Z15.09 – Genetic susceptibility to other malignant neoplasm |
| LOINC Code | 21648‑9 – CDKN2A gene mutation analysis in Blood or Tissue by Sequencing |
| DHA Facility License & Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians